Literature DB >> 31023348

National survey of patient specific IMRT quality assurance in China.

Yuxi Pan1, Ruijie Yang2, Shuming Zhang1, Jiaqi Li1, Jianrong Dai3, Junjie Wang1, Jing Cai4.   

Abstract

BACKGROUND: To analyze and present the China's national survey on patient-specific IMRT quality assurance (QA).
METHODS: A national survey was conducted in all radiotherapy centers in China to collect comprehensive information on status of IMRT QA practice, including machine, technique, equipment, issues and suggestions.
RESULTS: Four hundred and three centers responded to this survey, accounting for 56.92% of all the centers implementing IMRT in China. The total number of medical physicists and the total number of patients treated with IMRT annually in these centers was 1599 and 305,000 respectively. All centers implemented measurement-based verification. Point dose verification and 2D dose verification was implemented in 331 and 399 centers, respectively. Three hundred forty-eight centers had 2D arrays, and 52 centers had detector devices designed to measure VMAT beams. EPID and film were used in 78 and 70 centers, respectively. Seventeen and 20 centers used log file and 3D DVH analysis, respectively. One hundred sixty-eight centers performed measurement-based verification not for each patient based on different selection criteria. The techniques and methods varied significantly in both point dose and dose distribution verification, from evaluation metrics, criteria, tolerance limit, and steps to check failed IMRT QA plans. Major issues identified in this survey were the limited resources of physicists, QA devices, and linacs.
CONCLUSIONS: IMRT QA was implemented in all the surveyed centers. The practice of IMRT QA varied significantly between centers. An increase in personnel, QA devices and linacs is highly desired. National standard, guideline, regulation and training programs are urgently needed in China for consistent and effective implementation of IMRT QA.

Entities:  

Keywords:  IMRT; National survey; Patient-specific QA

Mesh:

Year:  2019        PMID: 31023348      PMCID: PMC6482589          DOI: 10.1186/s13014-019-1273-5

Source DB:  PubMed          Journal:  Radiat Oncol        ISSN: 1748-717X            Impact factor:   3.481


  6 in total

1.  Application of TG-218 action limits to SRS and SBRT pre-treatment patient specific QA.

Authors:  Yuqing Xia; Justus Adamson; Yana Zlateva; Will Giles
Journal:  J Radiosurg SBRT       Date:  2020

2.  Optimizing the Region for Evaluation of Global Gamma Analysis for Nasopharyngeal Cancer (NPC) Pretreatment IMRT QA by COMPASS: A Retrospective Study.

Authors:  Wenli Lu; Ying Li; Wei Huang; Haixia Cui; Hanyin Zhang; Xin Yi
Journal:  Front Oncol       Date:  2022-06-14       Impact factor: 5.738

3.  Dosimetric Evaluation of the Treatment Plan on Indigenous Heterogeneous Phantoms using Analytical Anisotropic Algorithm and Acuros-XB Algorithm for Different Photon Energies.

Authors:  Vinod Kumar Gangwar; Om Prakash Gurjar; Lalit Kumar; Avinash Agarwal; Vineet Kumar Mishra; Surendra Prasad Mishra; Saket Pandey
Journal:  J Biomed Phys Eng       Date:  2022-06-01

4.  Commissioning and clinical implementation of an Autoencoder based Classification-Regression model for VMAT patient-specific QA in a multi-institution scenario.

Authors:  Ruijie Yang; Xueying Yang; Le Wang; Dingjie Li; Yuexin Guo; Ying Li; Yumin Guan; Xiangyang Wu; Shouping Xu; Shuming Zhang; Maria F Chan; Lisheng Geng; Jing Sui
Journal:  Radiother Oncol       Date:  2021-06-21       Impact factor: 6.901

5.  Development of a Monte Carlo based robustness calculation and evaluation tool.

Authors:  Hannes A Loebner; Werner Volken; Silvan Mueller; Jenny Bertholet; Paul-Henry Mackeprang; Gian Guyer; Daniel M Aebersold; Marco F M Stampanoni; Peter Manser; Michael K Fix
Journal:  Med Phys       Date:  2022-05-04       Impact factor: 4.506

6.  Survey of patient-specific quality assurance practice for IMRT and VMAT.

Authors:  Gordon H Chan; Lee C L Chin; Ady Abdellatif; Jean-Pierre Bissonnette; Lesley Buckley; Daria Comsa; Dal Granville; Jenna King; Patrick L Rapley; Aaron Vandermeer
Journal:  J Appl Clin Med Phys       Date:  2021-06-19       Impact factor: 2.102

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.